Reuters logo
Portola Pharma's lead drug meets main goal in mid-stage study
June 11, 2014 / 12:55 PM / 3 years ago

Portola Pharma's lead drug meets main goal in mid-stage study

June 11 (Reuters) - Portola Pharmaceuticals said its experimental drug reversed the effect of a generic blood thinner in a mid-stage study, indicating the drug would allow coagulation in cases of excessive bleeding or urgent surgery.

The company’s shares rose 7 percent in premarket trading.

The drug, andexanet alfa, was well tolerated in the study and no serious adverse events were reported, Portola said in a statement on Wednesday. (Reporting by Anjali Rao Koppala in Bangalore; Editing by Kirti Pandey)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below